Trial Profile
A phase III study of E7777 in patients with cutaneous T-cell lymphoma.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Registrational; Therapeutic Use
- 15 Sep 2022 According to a Citius Pharmaceuticals media release, BLA submission is being prepared for the second half of 2022.
- 15 Feb 2022 Status changed from planning to recruiting as per Citius Pharmaceuticals media release.
- 05 Apr 2016 New trial record